Three monoclonal antibodies (MAbs) to a pilus colonization factor (colonization factor antigen Ill [CFA/III]) of human enterotoxigenic Escherichia coli (ETEC) were developed and characterized. All of the MAbs isolated belonged to the immunoglobulin G2a subclass. The specificity of these MAbs for CFA/IAl pili was demonstrated by the immunogold-labeling technique. The presence of more than one epitope in CFA/III phli was suggested. One of the three MAbs appears to recognize a polymeric conformational epitope(s) of CFA/III. CFAIIII antigenicity distinct from that of other pilus colonization factors of ETEC was demonstrated by both a bacterial agglutination test and a sandwich enzyme-linked immunosorbent assay using the MAbs. Of the 100 strains of ETEC isolated from persons with traveler's diarrhea, 8% were found to carry CFA/II pili. Two enzyme-linked immunosorbent assay systems which could detect as little as several or 50 ng of CFA/III per ml were developed.
Enterotoxigenic Escherichia coli (ETEC) is one of the most important causes of diarrhea, with worldwide distribution (3, 17) . Two steps are thought to be involved in the pathogenesis of ETEC (2, 10) .
Step 1 is colonization of the intestinal epithelium by the organism. This event is related to the production of specific surface antigens that can usually be identified morphologically as pili (10, 16) and are sometimes called colonization factor antigens (CFAs) (8, 9) for human ETEC.
Step 2 is production of heat-labile or heatstable enterotoxin or both.
Several types of pilus colonization factors of ETEC have been reported. These include CFA/I (9), CFA/II (8), PCF8775 (CFA/IV) (21, 24) , and others (6, 7, 10, 16, 20) . No heterogeneity of CFAII has been demonstrated, but antigenic heterogeneity of CFA/II (4, 18, 22, 23) and CFAIIV (21, 24) has been reported. We found a possible new pilus colonization factor of human ETEC and named it CFA/III (12) . Darfeuille et al. (5) also independently reported a CFA/III. Recently, Manning et al. (19) mentioned that the CFA/III reported by Darfeuille et al. (5) appears to be CFA/I, whereas that reported by us (12) is unique.
We describe here the production and partial characterization of monoclonal antibodies (MAbs) to the CFA/III reported by us (12) and demonstrate its antigenic specificity by using these MAbs. We also report the development of an enzyme-linked immunosorbent assay (ELISA) that uses MAbs to detect CFA/III antigen.
MATERIALS AND METHODS
Bacterial strains. We used the following five control ETEC strains, which originated from humans: H10407, which produces CFA/I; TH61 and C9lf, which produce CS2 (a subtype of CFA/II); M424C1, which produces both CS1 and CS3 (subtypes of CFA/II); and TH31, which produces CFA/III (13 used. Detailed procedures for selection of cases for stool examination and isolation of ETEC were described previously (1). Test organisms were grown on CFA agar at 37°C for 18 to 24 h (12, 13).
Purification of CFA/III pili. CFA/III pili were purified by sequential column chromatography on Sepharose 4B and Phenyl-Sepharose CL-4B as described previously (12) . CFA/ I and CFA/II (CS2) were also purified as described previously (13) . CFA/II (CS1 plus CS3) was partially purified by ammonium sulfate fractionation and column chromatography on Sepharose 4B and Phenyl-Sepharose CL-4B columns as described previously (12) .
Preparation of MAbs. For mouse immunization, a purified CFA/III suspension in phosphate-buffered saline (PBS; 0.01 M, pH 7.2) was mixed with an equal amount of Freund complete adjuvant and then 0.4 ml of the mixture, containing 20 ,ug of CFA/III, was injected intraperitoneally into BALB/c mice. After 4 a Polyclonal rabbit antisera (13) were used.
electrophoresis with a 12% acrylamide gel as described previously (13) and then electrophoretically transferred to nitrocellulose paper (Bio-Rad Laboratories, Richmond, Calif.) as reported by Towbin et al. (25) , except that electrophoresis was performed at 20 V for 18 h with an NA-1510 transfer apparatus (Nihon Eido Co. Ltd., Tokyo, Japan). After nitrocellulose paper was blocked with 3% bovine serum albumin, the paper was put in the culture supernatant of the hybridomas and then in the solution containing peroxidase-conjugated rabbit anti-mouse immunoglobulin (Zymed) diluted 1:1,000 with PBS-Tween 20 overnight at 4°C with gentle shaking. The enzyme activity was detected with a substrate of 4-chloro-1-naphthol.
Bacterial agglutination test. The strains tested were cultured on CFA agar plates and then harvested in PBS. A 10-,ul sample of the bacterial suspension (about 108 cells per ml) was mixed with 10 Rl of a MAb to CFA/III on a glass slide.
The mixture was gently rotated for 2 min, and then bacterial agglutination was observed by the naked eye (14) . Polyclonal rabbit antisera to CFAII and CFA/II (CS2 and CS1 plus CS3) prepared as described previously (12, 13) were also used.
Immunogold staining technique. Anti-mouse immunoglobulin antibody-coated colloidal gold particles (Auro Probe EM; Janssen Life Sciences Products, Piscataway, N.J.) 15 nm in diameter were used to demonstrate antibody reactivity to CFA/III pili as recommended by the manufacturer. Briefly, strain TH31, H10407, C9lf, or M424C1 was allowed to react with diluted (1:5,000) mouse ascites fluid induced by hybridomas and then Auro Probe EM reagent on the grid. After these procedures were completed, the grid was negatively stained with 1% phosphotungstic acid and examined by transmission electron microscopy (HU-12A; Hitachi) (13) . Methods) were developed. For system 2 (see Materials and Methods), MAb 121-42B was used for enzyme (alkaline phosphatase) labeling. The system 1 and 2 ELISAs were sensitive enough to detect several nanograms and about 50 ng of purified CFA/III per ml, respectively (Fig. 3) . When the ratio of the optical density of a test sample to that of a negative control was more than 1.5, the sample was considered positive. The ELISA was reactive only with CFA/III and not with CFA/I or CFA/II (CS2 or CS1 plus CS3) (Fig.  4) (5-10, 12, 16, 20, 24) . We have found a new such factor named CFA/III (12, 14) after analyzing various ETEC strains isolated from persons with traveler's diarrhea at the Osaka Airport Quarantine Station (1, 14) . We report here for the first time the production of MAbs developed against CFA/III. The specificity of these MAbs for CFA/III pili was demonstrated by an immunogold-labeling technique (Fig. 1) , bacterial agglutination (Table 2) , and ELISAs (Fig. 4) using MAbs developed in this study. All of these analyses prove that the antigenicity of CFA/III is distinct from those of others, such as CFA/I and CFA/II (CS2 and CS1 plus CS3), suggesting that CFA/III is (Table 4) . Our data on 100 ETEC strains selected at random from persons with traveler's diarrhea demonstrate that 8% possessed CFA/III, suggesting the importance of CFAIIII as one of the major pilus colonization factors of ETEC. Thus, MAbs developed in this study will be a valuable tool for identifying ETEC carrying CFA/III. By using MAbs produced in this study, we developed two sandwich ELISA systems with high sensitivity for detection of CFA/III. Although ELISA system 1 (double-antibody system) is about 10-fold higher in sensitivity, ELISA system 2 (one-antibody system) is more rapid and practical. This may be useful for direct identification of CFA/III in diarrheal stools and thus for rapid diagnosis of infection with ETEC carrying CFAIIII. We are now examining this interesting possibility.
